UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

High Performance Computing: 9th Latin American Conference, CARLA 2022, Porto Alegre, Brazil, September 26-30, 2022, Revised Selected Papers

1st Edition 2022, 2022

Volltextzugriff (PDF)

Global challenges in breast cancer detection and treatment

Breast (Edinburgh), 2022-03, Vol.62 (Suppl 1), p.S3-S6

Barrios, Carlos H.

2022

Volltextzugriff (PDF)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Journal of clinical oncology, 2021-04, Vol.39 (12), p.1349-1359

2021

Volltextzugriff (PDF)

Enhancing global access to cancer medicines

CA: a cancer journal for clinicians, 2020-03, Vol.70 (2), p.105-124

2020

Volltextzugriff (PDF)

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1872-1882

2021

Volltextzugriff (PDF)

High Performance Computing: 10th Latin American Conference, CARLA 2023, Cartagena, Colombia, September 18-22, 2023, Revised Selected Papers

1, 2024

Volltextzugriff (PDF)

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Journal of clinical oncology, 2010-02, Vol.28 (6), p.1061-1068

2010

Volltextzugriff (PDF)

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2849-2853

2013

Volltextzugriff (PDF)

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3337-3344

2012

Volltextzugriff (PDF)

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study

PloS one, 2018-08, Vol.13 (8), p.e0202865-e0202865

2018

Volltextzugriff (PDF)

Boosting Advanced Computational Applications and Resources in Latin America through Collaboration and Sharing

Computing in science & engineering, 2018-05, Vol.20 (3), p.39-48

2018

Volltextzugriff (PDF)

Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil

JCO global oncology, 2021, Vol.7 (7), p.46-55

2021

Volltextzugriff (PDF)

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

The New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339

2020

Volltextzugriff (PDF)

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

BMC cancer, 2019-06, Vol.19 (1), p.620-620, Article 620

2019

Volltextzugriff (PDF)

Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)

JCO global oncology, 2021-12, Vol.7 (7), p.649-658

2021

Volltextzugriff (PDF)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer

JNCI : Journal of the National Cancer Institute, 2021-11, Vol.113 (12), p.1733-1743

2021

Volltextzugriff (PDF)

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2946-2956

2022

Volltextzugriff (PDF)

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline

JCO global oncology, 2024-01, Vol.10 (10), p.e2300285-e2300285

2024

Volltextzugriff (PDF)

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

European journal of cancer (1990), 2013-04, Vol.49 (6), p.1287-1296

2013

Volltextzugriff (PDF)

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2014-09, Vol.32 (25), p.2765-2772

2014

Volltextzugriff (PDF)

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer

Frontiers in oncology, 2017-03, Vol.7, p.26-26

2017

Volltextzugriff (PDF)

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

NPJ breast cancer, 2023-04, Vol.9 (1), p.32-32, Article 32

2023

Volltextzugriff (PDF)

Reply to Y. Usui et al

Journal of clinical oncology, 2020-06, Vol.38 (18), p.2113-2114

2020

Volltextzugriff (PDF)

1 – 25 von 302

Suche als RSS-Feed

Aktive Filter

ThemaBreast Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(247)
Mit Volltextzugriff
(259)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(141)
Life Sciences & Biomedicine
(90)
Humans
(68)
Oncology
(53)
Technology
(47)
Computer Science
(44)
Female
(42)
Computer Science, Theory & Methods
(39)
Middle Aged
(35)
Male
(32)
Aged
(31)
Adult
(29)
Aged, 80 And Over
(17)
Computer Science, Artificial Intelligence
(17)
Computer Science, Interdisciplinary Applications
(17)
Biological And Medical Sciences
(16)
Treatment Outcome
(16)
Young Adult
(13)
Disease-Free Survival
(12)
Lung Neoplasms - Drug Therapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

High Performance Computing: 9th Latin American Conference, CARLA 2022, Porto Alegre, Brazil, September 26-30, 2022, Revised Selected Papers

Global challenges in breast cancer detection and treatment

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Enhancing global access to cancer medicines

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

High Performance Computing: 10th Latin American Conference, CARLA 2023, Cartagena, Colombia, September 18-22, 2023, Revised Selected Papers

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study

Boosting Advanced Computational Applications and Resources in Latin America through Collaboration and Sharing

Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)

PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Reply to Y. Usui et al

Aktive Filter

Suchergebnisse filtern